New oral anticoagulants for the prevention of thromboembolic events in patients with atrial fibrillation
Canadian Agency for Drugs and Technologies in Health
Record ID 32010001163
English
Authors' objectives:
Compare the clinical effectiveness and safety of these anticoagulants with warfarin
Determine the cost and economic impact of these anticoagulants compared with warfarin
Compare these anticoagulants with optimal warfarin therapy
Review available strategies to identify over-anticoagulation and bleeding risk with new oral anticoagulants
Review available strategies to prevent and treat bleeding associated with new oral anticoagulants
Develop recommendations for the use of new oral anticoagulants
Determine what tools are available to help health practitioners and consumers manage therapy with new oral anticoagulants and, if needed, develop new tools
Authors' recommendations:
Compared with warfarin, the benefits of new oral anticoagulants are small. The estimated number of patients who would avoid a stroke or other blood clot if treated with a new drug rather than warfarin was 2 to 6 people for every 1,000 patients treated per year.
Bleeding risks for patients treated with the newer drugs compared with warfarin were similar overall, with a modest decrease in intracranial bleeding and a small increase in gastrointestinal bleeding. A systematic review showed that there is no reversal agent or proven management strategy if bleeding occurs with the new drugs. The cost-effectiveness of the new drugs was uncertain.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.cadth.ca/en/products/therapeutic-reviews/anticoagulants/reports
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Thromboembolism
- Venous Thrombosis
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.